Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1612-1615. doi: 10.1164/rccm.201704-0796LE. No abstract available.

2.

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M.

SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017.

3.

More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Diacon AH, Van Baelen B, Theeuwes M.

N Engl J Med. 2016 Dec 29;375(26):2609-10. No abstract available.

PMID:
28032964
4.

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.

Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, Kamali A, Kotze P, Louw C, Mabude Z, Miti N, Kusemererwa S, Tempelman H, Carstens H, Devlin B, Isaacs M, Malherbe M, Mans W, Nuttall J, Russell M, Ntshele S, Smit M, Solai L, Spence P, Steytler J, Windle K, Borremans M, Resseler S, Van Roey J, Parys W, Vangeneugden T, Van Baelen B, Rosenberg Z; Ring Study Team.

N Engl J Med. 2016 Dec 1;375(22):2133-2143.

5.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

6.

Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.

Kagan RM, Johnson EP, Siaw MF, Van Baelen B, Ogden R, Platt JL, Pesano RL, Lefebvre E.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):151-9. doi: 10.1089/AID.2013.0123. Epub 2013 Aug 14.

7.

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.

De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G.

J Viral Hepat. 2013 Jun;20(6):395-403. doi: 10.1111/jvh.12046. Epub 2013 Jan 10.

PMID:
23647956
8.

Telaprevir-related dermatitis.

Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS.

JAMA Dermatol. 2013 Feb;149(2):152-8.

PMID:
23560295
9.

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G.

Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962.

PMID:
22806681
10.

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.

Kavanagh S, Van Baelen B, Schäuble B.

J Alzheimers Dis. 2011;27(3):521-30. doi: 10.3233/JAD-2011-110417.

PMID:
21891871
11.

Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment.

Gaudig M, Richarz U, Han J, Van Baelen B, Schäuble B.

Curr Alzheimer Res. 2011 Nov;8(7):771-80.

PMID:
21707533
12.

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M.

Gastroenterology. 2011 Sep;141(3):881-889.e1. doi: 10.1053/j.gastro.2011.05.046. Epub 2011 May 31.

PMID:
21699786
13.

Galantamine and behavior in Alzheimer disease: analysis of four trials.

Kavanagh S, Gaudig M, Van Baelen B, Adami M, Delgado A, Guzman C, Jedenius E, Schäuble B.

Acta Neurol Scand. 2011 Nov;124(5):302-8. doi: 10.1111/j.1600-0404.2011.01525.x. Epub 2011 May 26.

PMID:
21615354
14.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.

Kavanagh S, Howe I, Brashear HR, Wang D, van Baelen B, Todd M, Schwalen S.

Curr Alzheimer Res. 2011 Mar;8(2):175-86.

15.

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S.

AIDS. 2009 Sep 24;23(15):2005-13. doi: 10.1097/QAD.0b013e328330abaa.

PMID:
19724191
16.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650
17.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
18.

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Diego Miralles G.

HIV Med. 2009 May;10(5):318-27. doi: 10.1111/j.1468-1293.2008.00690.x. Epub 2009 Feb 5.

19.

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.

Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frölich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van Baelen B, Hammond GL, van Oene JC, Schwalen S.

Lancet Neurol. 2009 Jan;8(1):39-47. doi: 10.1016/S1474-4422(08)70261-8. Epub 2008 Nov 29.

PMID:
19042161
20.

Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.

Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, Kavanagh S.

Int J Geriatr Psychiatry. 2009 May;24(5):479-88. doi: 10.1002/gps.2141.

PMID:
18985627
21.

Analyses of mortality risk in patients with dementia treated with galantamine.

Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin JA, Battisti WP, Kavanagh S.

Acta Neurol Scand. 2009 Jan;119(1):22-31. doi: 10.1111/j.1600-0404.2008.01047.x. Epub 2008 Jun 1.

PMID:
18518863
22.

Resistance profile of darunavir: combined 24-week results from the POWER trials.

de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88. doi: 10.1089/aid.2007.0173.

PMID:
18327986
23.

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, van Baelen B, Lefebvre E; POWER 2 Study Group.

AIDS. 2007 Mar 30;21(6):F11-8.

PMID:
17413685
24.

Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis.

Feldman HH, Van Baelen B, Kavanagh SM, Torfs KE.

Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):29-36.

PMID:
15764869
25.

Effects of galantamine in patients with mild Alzheimer's disease.

Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S.

Curr Med Res Opin. 2004 Nov;20(11):1815-20.

PMID:
15537482
26.
27.

The effects of galantamine treatment on caregiver time in Alzheimer's disease.

Sano M, Wilcock GK, van Baelen B, Kavanagh S.

Int J Geriatr Psychiatry. 2003 Oct;18(10):942-50.

PMID:
14533127
28.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
29.

Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.

Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S.

Int J Clin Pract. 2002 Sep;56(7):509-14.

PMID:
12296613
30.

A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.

Fleischhacker WW, Lemmens P, van Baelen B.

Pharmacopsychiatry. 2001 May;34(3):104-10.

PMID:
11434401
31.

Effects of risperidone on affective symptoms in patients with schizophrenia.

Peuskens J, Van Baelen B, De Smedt C, Lemmens P.

Int Clin Psychopharmacol. 2000 Nov;15(6):343-9.

PMID:
11110010
32.
33.

Prolactin levels and adverse events in patients treated with risperidone.

Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M.

J Clin Psychopharmacol. 1999 Feb;19(1):57-61.

PMID:
9934944

Supplemental Content

Loading ...
Support Center